Non-allergic rhinitis: a case report and review by Nozad, Cyrus H et al.
REVIEW Open Access
Non-allergic rhinitis: a case report and review
Cyrus H Nozad
1*, L Madison Michael
2,3, D Betty Lew
1, Christie F Michael
1
Abstract
Rhinitis is characterized by rhinorrhea, sneezing, nasal congestion, nasal itch and/or postnasal drip. Often the first
step in arriving at a diagnosis is to exclude or diagnose sensitivity to inhalant allergens. Non-allergic rhinitis (NAR)
comprises multiple distinct conditions that may even co-exist with allergic rhinitis (AR). They may differ in their pre-
sentation and treatment. As well, the pathogenesis of NAR is not clearly elucidated and likely varied. There are
many conditions that can have similar presentations to NAR or AR, including nasal polyps, anatomical/mechanical
factors, autoimmune diseases, metabolic conditions, genetic conditions and immunodeficiency. Here we present a
case of a rare condition initially diagnosed and treated as typical allergic rhinitis vs. vasomotor rhinitis, but found to
be something much more serious. This case illustrates the importance of maintaining an appropriate differential
diagnosis for a complaint routinely seen as mundane. The case presentation is followed by a review of the poten-
tial causes and pathogenesis of NAR.
Introduction
The term rhinitis can be used to describe many distinct
entities with varying pathogeneses, despite similar pre-
sentations. Generally, rhinitis is considered allergic if
significant inhalant allergy is diagnosed and is consid-
ered non-allergic when symptomatology is perennial or
periodic and not IgE mediated. Thus non-allergic rhini-
tis (NAR) comprises a mixed bag of conditions ranging
from vasomotor rhinitis (VMR) to hormonally induced
rhinitis.
Overall, rhinitis results in significant cost to the world
population. In 2002, the direct and indirect costs for
allergic rhinitis (AR) were estimated to be $7.3 billion
and $4.28 billion, respectively [1]. Given that an esti-
mated 1 in 3 patients with rhinitis are diagnosed with
NAR, with 19 million people in the United States alone,
it is reasonable to conclude that NAR also results in a
significant economic burden [2-4].
NAR is a condition primarily seen in adulthood with
70% of cases developing after the age of 20. There is a
greater prevalence among females compared to males
[5,6], and the overall prevalence of NAR in industria-
lized countries has ranged from 20-40% [7]. The follow-
ing case presentation is an example of a patient with
typical NAR symptoms who fits the epidemiological
profile, but who presented atypically, failed to respond
to standard therapy and was subsequently found to have
a much more serious underlying condition.
Case Report
A 52 year old African American female presented to our
outpatient allergy clinic with a chief complaint of pro-
fuse “runny nose” for 1 week. She initially attributed the
rhinorrhea to prolonged moth ball exposure in her
small office space. Prior to her visit she had been seen
by her primary care provider and in the emergency
department. Both treated her for allergic rhinitis vs.
vasomotor rhinitis with intranasal corticosteroids and
oral antihistamines. She also complained of a diffuse
headache, imbalance, cough and right ear fullness. She
denied any history of previous rhinitis symptoms, eye
symptoms or sneezing. Her past medical history was sig-
nificant for hypertension, hypercholesterolemia, diabetes
mellitus (poorly controlled) and excision of a benign
scalp lesion at age 18. Family history was significant for
a father and eight siblings with allergic rhinitis and one
brother with asthma. Her social history was significant
for pet and tobacco smoke exposure. She denied any illi-
cit drug use. Review of systems was negative for trauma,
fevers, chills, weight loss, night sweats, shortness of
breath, chest pain, nausea, vomiting or diarrhea; and
positive for, diffuse headaches, unsteadiness and a cough
productive of clear sputum that was worse when supine.
On physical exam her vital signs were: BP 172/86, P
89, R 18, T 36.2 C, W 95 kg. Generally, she presented
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distress. She had a normocephalic/atraumatic head, tym-
panic membranes were clear, and conjunctivae were
clear. She had copious clear nasal discharge from the
right naris with a continual drip. The nasal mucosa was
otherwise moist and mildly erythematous; with slightly
atrophic turbinates. There was no chest deformity. The
lungs were clear to auscultation without wheezes, rubs
or rhonchi. Cardiovascularly, she had a regular rate and
rhythm without murmurs, rubs or gallops. The abdo-
men was soft, non-tender/non-distended and no masses
were palpated. Skin exam revealed no lesions. Extremity
examination did not reveal any cyanosis, clubbing or
edema. Lastly she had no enlarged cervical lymph nodes.
A sample of her nasal rhinorrhea was sent to the lab
to analyze for beta-2 transferrin. She was then sent for a
stat CT scan of her head. The patient’s rhinorrhea sam-
ple was positive for beta-2 transferrin, consistent with a
cerebrospinal fluid leak (CSF). The CT scan showed
mucosal thickening of the ethmoid sinuses and nasal
septal deviation, but no intracranial findings to explain
CSF leak. Consultation with Neurosurgery and ENT
were made. When the leak failed to resolve sponta-
neously, she underwent a CT cisternogram to localize
the leak. A defect was identified in the cribriform plate
bilaterally with CSF extension into several bilateral eth-
moid air cells, Figure 1. She underwent an endoscopic
ethmoidotomy and repair of her cerebrospinal fluid leak
by ENT. After surgery, neurosurgery placed a lumbar
drain for 72 hours to divert the CSF in order for the
repair to properly seal. Repeat CT cisternogram 1
month later no longer showed evidence of CSF leak.
Cerebrospinal Rhinorrhea Etiology,
Diagnosis and Treatment
C S Fi sp r o d u c e di nt h ec h o r o i dp l e x u sa tar a t eo f
350-500 ml per day. The total adult volume is 90-150
m l .T h i sv o l u m ei st u r n e do v e r3 - 5t i m e sp e rd a yv i a
continual absorption by the arachnoid villa. The etiolo-
gies of CSF leak include accidental trauma from a closed
head injury (44%), surgical trauma (29%), tumors (22%),
congenital skull base deformities (rare), and spontaneous
leak (3-4%, but in some series are as high as 15-20%)
due to increased intracranial pressure (ICP) [8-10],
Figure 2.
As in our case, the diagnosis starts with identification
of the rhinorrhea as CSF. The fluid is analyzed for beta-
2 transferrin, which is formed by the conversion of
beta-1 transferrin into beta-2 transferrin by cerebral
neuraminidase [11]. Beta-2 transferrin is only found in
the CSF, vitreous humor of the eye and perilymph.
Next, the site of the leak must be identified. A high
resolution CT scan of the head can evaluate the parana-
sal sinuses as well as the skull base. Adding intrathecal
Figure 1 Preoperative CT scan of the head. A preoperative CT
scan of the head with intrathecal contrast was done to localize the
CSF leak. The frontal view is shown here. The scan shows a defect
in the cribriform plate with confluent CSF extension into several
bilateral ethmoid air cells, evidenced by the higher intensity signal
of the contrast. Secondarily, there is mucosal thickening in the
ethmoid and maxillary sinuses.
Figure 2 Etiology of CSF Rhinorrhea. CSF leak can be attributed
to the following causes: Accidental trauma from a closed head
injury (44%), surgical trauma (29%), tumors (22%), spontaneously
due to increased intracranial pressure (ICP) (3-4%, but in some series
are as high as 15-20%) and congenital skull base deformities (rare)
[8-10].
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patient has an inactive or intermittent leak, they may
have a negative CT scan. CT scan has a sensitivity ran-
ging from 48 to 96% [11,12]. Magnetic resonance cister-
nography is another method of localization of CSF leaks
and has a sensitivity of 92-100%. MRI is also used as an
adjunct test for further characterization of meningoen-
cephalocele, if present [13].
Patients with a spontaneous CSF leak, due to an asso-
ciated increase in intracranial pressure can have charac-
teristic findings. These findings are, a broadly thinned
and attenuated skull base, dehiscence of the ethmoid
roof, arachnoid pits (from bony impressions from ara-
chnoid villa), pneumatization of the lateral sphenoid
sinus recess and meningoencephalocele formation
[14-16]. The most common sites for a leak in these
patients include, the lateral recess of the sphenoid sinus
and the ethmoid roof or cribriform [11].
Treatment can consist of a traditional open craniot-
omy with repair of the defect. This approach has a suc-
cess rate of 70-80% [17,18]. Newer endoscopic repairs
have shown greater success, with rates >90% and avoid
the morbidity associated with craniotomy [19]. For
patients with elevated intracranial pressure, cerebrosp-
inal fluid diversion procedures (i.e. ventriculoperitoneal
shunt or lumboperitoneal shunt) may be needed to suc-
cessfully stop the egress of fluid. Lastly, some patients
will have spontaneous closure of their leak.
Non-Allergic Rhinitis Classification
NAR consists of multiple entities, some of which share
components of both AR and NAR. One way of further
classifying these conditions distinguishes pure non-aller-
gic rhinitis (without any component of AR), occupa-
tional rhinitis and other rhinitis syndromes. The
pathogeneses of these different conditions is not clearly
defined and there are many proposed mechanisms.
Non-Allergic Rhinitis
Vasomotor or idiopathic rhinitis (VMR) is the most
commonly diagnosed form of NAR, accounting for
~60% cases in one series [5]. VMR is characterized by
sporadic or persistent nasal symptoms that are trigged
by: strong smells, cold air, changes in temperature,
humidity, barometric pressure, strong emotions, alcohol
and changes in hormone levels. Diagnosis is made clini-
cally and onset is typically in adulthood. Intranasal corti-
costeroids and intranasal antihistamines are the
mainstay of therapy.
Gustatory rhinitis typically occurs after ingestion of
heated foods, spicy foods or alcohol. Profuse rhinorrhea
may be vagally mediated, due to a food allergy and/or
other undefined mechanisms. Treatment consists of
intranasal ipratropium bromide as needed.
Infectious rhinitis may be acute or chronic in nature.
Symptoms include nasal congestion, mucopurulent nasal
discharge, frontal headache, olfactory disturbances, post-
nasal drainage and cough. Viral infections account for
as many as 98% of acute infectious rhinitis in young
children [20]. Treatment is symptomatic, unless a bac-
terial cause is suspected and topical antibacterial agents
can be used in some cases.
Non-allergic rhinitis with eosinophilia syndrome
(NARES) usually develops in adulthood and is charac-
terized by year round nasal symptoms such as, profuse
rhinorrhea and nasal congestion. These patients have
negative allergy skin testing and normal serum IgE
levels. Classically, nasal smears have greater than 5% to
greater than 20% eosinophils [21]. Many of these
patients may develop aspirin (ASA) sensitivity, sinusitis,
nasal polyps, and asthma. These patients are also at
increased risk of developing obstructive sleep apnea
[22].
There is also a variant of NARES called blood eosino-
philia-nonallergic rhinitis syndrome (BENARES). These
patients share the same characteristics as patients with
NARES except they lack nasal eosinophilia and instead
have elevated serum eosinophil levels. Intranasal corti-
costeroids are the treatment of choice for both NARES
and BENARES [5,23].
Occupational Rhinitis
Occupational rhinitis can develop after exposures, typi-
cally in a work environment, and may be allergic or non
allergic in nature. There are four types of occupational
rhinitis. The first type is annoyance rhinitis, which is
purely subjective, typically fragrance-induced, and
occurs without evidence of nasal inflammation. The sec-
ond type is irritant-induced rhinitis, and manifests as
inflammation of the nasal mucosa without apparent
immunologic or allergic basis [24].
The third type is corrosive rhinitis, following exposure
to high concentrations of irritating and soluble chemical
gases. Examples include ammonia and pesticides. The
fourth and final type is allergic rhinitis, with evidence of
an IgE mediated reaction to an occupational exposure.
An example would be latex allergy in a healthcare
worker. Treatment in all of these different rhinitis types
consists of nasal saline to remove particulate matter,
nasal corticosteroids, nasal antihistamines and avoid-
ance. The exception is corrosive rhinitis, in which case
avoidance is the only option.
Other Rhinitis Syndromes
Hormonally induced rhinitis, includes menstrual cycle
related rhinitis and rhinitis of pregnancy. Rhinitis of
pregnancy typically begins in the 2
nd trimester with
severe congestion and resolves about 2 weeks
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or nasal lavage. Exercise may lead to physiologic nasal
vasoconstriction. External nasal dilators (e.g. strips
applied to the bridge of the nose to buttress open the
nares) may be effective for patients with pregnancy-
related nocturnal nasal congestion. Typically, rhinitis of
pregnancy requires no specific pharmacologic interven-
tion and intranasal glucocorticoids have not been shown
to be effective. There is anecdotal evidence to support
the use of nasal ipratropium and pseudoephedrine;
therefore, these agents may be useful in patients who
are particularly symptomatic. However, pseudoephedrine
should be avoided in the first trimester of pregnancy
and in women with hypertension.
Rhinitis medicamentosa is characterized by severe
nasal congestion, due to a rebound effect from overuse
of topical decongestants, such as oxymetazoline, an imi-
dazole, and phenylephrine, a sympathomimetic amine.
Treatment consists of topical nasal corticosteroids and/
or oral corticosteroids, with progressive withdrawal of
the topical decongestant over 3-7 days. Other medica-
tions can lead to nasal symptoms as a side effect, usually
congestion. Examples include ACE inhibitors, b-block-
ers, aspirin and NSAIDs.
Atrophic rhinitis is characterized by progressive nasal
atrophy, mucosal colonization with Klebsiella ozaenae or
other organisms, and a foul smelling nasal discharge. It
can be seen as a post surgical complication, i.e. status
post turbinectomy. Treatment consists of nasal lavage,
lubrication and topical antibiotics are used for muco-
purulent secretions lasting beyond 2 days. Oral antibio-
tics can also be used for acute infections. Surveillance
rhinoscopy should be performed at least twice a year if
the patient remains symptomatic [26]. The clinical pre-
sentations and treatments for non-allergic rhinitis are
summarized in Table 1.
Pathogenesis
The mechanisms underlying VMR are poorly understood.
Generally it is thought to arise from an imbalance of auto-
nomic input into the nasal mucosa. An initial stimulus
results in nasal congestion and/or rhinorrhea induced by
tachykinins from the central nervous system, which also
inhibit sympathetic mediators and thus further enhance
the parasympathetic response [27,28], see Figure 3.
Tai and Baraniuk suggested that sensory C-fiber sti-
mulation leads to release of substance P (SP) and calci-
tonin gene-related peptides (CGRP). This in turn leads
to increased plasma excretion and glandular secretion
(via acetylcholine and muscarinic receptors) manifesting
as pain and stuffiness [29]. Schierhorn et al. have shown
that ozone increases nasal mucosal levels of SP and neu-
rokinin A (NKA) [30]. NKA is also known to have a
similar structure and function to SP, resulting in
vascular smooth muscle contraction. Therefore, sensory
stimulation causes release of SP, CGRP, NKA with sub-
sequent nasal congestion and pain.
Groneberg et al. found elevated levels of neuropeptide
tyrosine (NPY), vasoactive intestinal peptide (VIP), and
SP in patients with irritant rhinitis caused by cigarette
smoke exposure, as compared to controls [31]. NPY is
primarily distributed around blood vessels and intranasal
administration of NPY has been shown to cause nasal
vasoconstriction and a decrease in nitric oxide levels
[32]. Noradrenaline also acts to vasoconstrict nasal
mucosal blood vessels [33]. VIP is an inhibitory neuro-
transmitter that can cause vasodilatation and hyperse-
cretion and thus congestion and rhinorrhea.
Furthermore, Acetylcholine (Ach) release leads to gland-
ular secretion and vasodilation [33].
The significance of the free radical, nitric oxide
(NO), in the context of rhinitis has been examined.
NO is generated by nitric oxide synthase (NOS), which
requires nicotinamide adenine dinucleotide phosphate
(NADPH) as a cofactor. NO is present only transiently,
therefore its presence and activity are inferred by the
measure of NADPH diaphorase levels in tissue, which
correlate with NOS activity. In patients with VMR,
epithelial damage correlates with increased NADPH
diaphorase activity and thus increased NO activity.
Collectively, these data suggest that NO, which has
known cytotoxic effects, can cause epithelium damage.
This damage could result in impaired mucociliary
clearance, loss of tight junctions and basement mem-
brane damage. This would in turn allow for increased
reactivity of afferent trigeminal fibers, secretory and
vascular reflexes resulting in the constellation of symp-
toms seen in VMR [34,35].
Analysis of nasal wash protein samples have shown that
the total protein and albumin concentration is higher in
patients with AR as opposed to NAR and controls, who
had the lowest concentrations. A 26 kDa protein, isolated
from nasal lavage, was found to be significantly elevated
in patients with AR as compared to patients with NAR
and controls. Although this protein is not well defined, it
is believed to originate from the nasal glands because it is
produced in normal subjects upon nasal provocation
with pilocarpine. It is thought that this may be used to
differentiate AR from NAR [36,37].
Trauma has also been implicated as a cause of VMR
[38]. Studies by Giannessi et al. have shown that in
patients with VMR, there was ciliary loss, absence of
tight junctions, marked distension of the intercellular
space, and loss of goblet cells [34].
IgE may also play a role in non-allergic rhinitis.
Patients with house dust mite sensitivity by history, nega-
tive inhalant allergy skin testing and RAST (radioallergo-
sorbent test), have been found to produce specific IgE
Nozad et al. Clinical and Molecular Allergy 2010, 8:1
http://www.clinicalmolecularallergy.com/content/8/1/1
Page 4 of 9antibodies in nasal secretions, but not in serum, upon
nasal provocation with house dust mite antigen [39].
A percentage of NAR patients have been found to have
increased numbers of nasal mucosal mast cells and eosi-
nophils. These IgE expressing cells further support the
role of a local allergic disease process in NAR [40,41].
Furthermore, labeled grass pollen has been shown to be
bound by mast cells in patients with NAR and negative
allergy inhalant testing [42]. Lastly, first line treatment is
usually topical corticosteroids lending further credence
to an underlying inflammatory immune mechanism.
Thromboxane A2 (TXA2) is a potent inflammatory
mediator. It binds via the TXA2 receptor which is a
G-protein coupled receptor. TXA2 receptor agonists
have been shown to increase nasal airway resistance
and nasal vascular permeability in guinea pigs [43].
Shirasaki et al. suggested that one of the isoforms of
the TXA2 receptor, TP alpha may play a role in
Table 1 Types of non-allergic rhinitis, clinical presentation and treatments
RHINITIS CLINICAL PRESENTATION TREATMENT
Non-Allergic Rhinitis:
Vasomotor Rhinitis Typically adult onset, sporadic or persistent nasal symptoms
trigged by strong smells, cold air, changes in temperature,
humidity, barometric pressure, strong emotions, alcohol and
changes in hormone levels.
Intranasal corticosteroids and/or intranasal antihistamines
are the mainstay of therapy
Gustatory Rhinitis Profuse rhinorrhea after ingestion of heated foods, spicy
foods or alcohol.
Intranasal ipratropium bromide as needed.
Infectious Rhinitis Nasal congestion, mucopurulent nasal discharge, frontal
headache, olfactory disturbances, postnasal drainage and
cough.
Symptomatic treatment for viral infections. Topical
antibacterial agents, i.e. mupirocin, for suspected bacterial
infections.
Non-allergic rhinitis
with eosinophilia
syndrome (NARES)
Typically adult onset. Individuals experience year round
profuse rhinorrhea and nasal congestion. These patients
have negative allergy skin testing and normal serum IgE
levels.
Intranasal corticosteroids.
Occupational Rhinitis:
[54-58]
Annoyance Patients report rhinitis symptoms that are purely subjective
after occupational exposures. Symptoms are typically
fragrance-induced, and occur without evidence of nasal
inflammation.
Avoidance of triggers, nasal saline, nasal corticosteroids and
nasal antihistamines.
Irritant Rhinitis symptoms after occupational exposure to irritants (e.
g. cigarette smoke), and these patients have objective
findings such as inflammation of the nasal mucosa without
apparent immunologic or allergic basis.
Avoidance of triggers, nasal saline, nasal corticosteroids and
nasal antihistamines.
Corrosive Rhinitis symptoms that occur after occupational exposure, to
high concentrations of irritating and soluble chemical gases
that in turn cause nasal inflammation which can break down
and ulcerate the nasal mucosa.
Avoidance of the inciting agent.
Allergic Rhinitis symptoms due to an IgE mediated reaction to an
occupational exposure.
Avoidance of triggers, nasal saline, nasal corticosteroids and
nasal antihistamines.
Other Rhinitis
Syndromes: [60-63]
Hormonally induced
Rhinitis
Includes menstrual cycle related rhinitis and rhinitis of
pregnancy. Rhinitis of pregnancy typically begins in the 2nd
trimester with severe congestion and resolves about 2
weeks postpartum[25].
Usually requires no specific pharmacologic intervention and
treatment consists of saline nose spray or nasal lavage.
External nasal dilator may be effective for patients with
pregnancy-related nocturnal nasal congestion. Intranasal
glucocorticoids have not been shown to be effective.
Rhinitis
Medicamentosa
Severe nasal congestion, due to a rebound effect from
overuse of topical decongestants, such as oxymetazoline
and phenylephrine.
Topical nasal corticosteroids and/or oral corticosteroids,
with progressive withdrawal of the topical decongestant
over 3-7 days.
Atrophic Rhinitis:
[66-68]
Primary Atrophic
Rhinitis
Secondary Atrophic
Rhinitis
Progressive nasal atrophy, mucosal colonization with
Klebsiella ozaenae or other organisms, and a foul smelling
nasal discharge. It can be seen as a post surgical
complication, i.e. status post turbinectomy.
Nasal lavage, lubrication and topical antibiotics are used for
mucopurulent secretions lasting beyond 2 days. Oral
antibiotics can also be used for acute infections.
Surveillance rhinoscopy should be performed at least twice
a year if the patient remains symptomatic[26].
Additional treatments for the various forms of rhinitis do exist. The most common or first line therapies are listed here.
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has been found in human inferior turbinate tissue, spe-
cifically on the smooth muscle layers of the venous
sinusoids, arterioles, epithelial cells and submucosal
glands in human nasal mucosa from patients with AR
and NAR. TXA 2 receptor antagonists have been
shown to reduce allergen induced nasal mucosal swel-
ling in patients with AR. Lastly, TXA2 receptor ago-
nists have been shown to induce leukocyte adhesion to
vascular walls, suggesting a role of TXA2 in the
inflammatory cascade [44].
In patients with gustatory rhinitis, Raphael et al. have
shown that increased levels of albumin and total protein
(without altering the ratio of albumin to total protein),
are identified in the nasal secretions of patients under-
going a food challenge. Furthermore, this effect can be
blunted by intranasal atropine, suggesting that atropine-
inhibitable muscarinic receptors play a large role in the
pathogenesis [45].
The pathogenesis of NARES is controversial and
poorly understood. One theory suggests that irritants
such as passive smoke exposure, induces a localized
allergic inflammatory response [46]. NARES may also
represent an early stage of aspirin sensitivity [47]. Lastly,
there is a proposed mechanism, that eosinophils may
directly damage nasal epithelial cells and lead to pro-
tracted mucociliary clearance [48-53].
The pathogenesis of occupational rhinitis is based on
the etiology of the rhinitis. Annoyance rhinitis does not
show any evidence of nasal mucosal inflammation. Irri-
tant-induced rhinitis triggers include tobacco smoke
exposure and symptoms are presumably due to SP
release, which has been shown to trigger a neurogenic,
primarily neutrophilic nasal inflammatory response
[54,55]. The agents that cause corrosive rhinitis cause
nasal inflammation which can break down and ulcerate
the nasal mucosa. Lastly, allergic occupational rhinitis is
IgE mediated and eosinophils, eosinophilic cationic pro-
tein, basophils and tryptase have been found in the
nasal lavage fluid of these patients [56-58].
Hormonally induced rhinitis can be seen in pregnancy.
It is unclear exactly how changes during pregnancy result
in rhinitis. Symptoms of rhinitis may have been present
prior to pregnancy but not fully appreciated [59]. An
increased circulating blood volume and progesterone
induced smooth muscle relaxation may lead to increased
nasal mucosal blood pooling and subsequent symptoms
of congestion [60]. In addition, high levels of estrogen,
prolactin, VIP and/or placental growth hormone have
been associated with increased nasal mucosal swelling
from increased vascular leakage, glandular secretion and
nasal vascular smooth muscle relaxation [61-63].
Rhinitis medicamentosa is believed to be caused not
by vasodilation, but interstitial edema [64]. The
Figure 3 Balance of autonomic inputs into nasal mucosa of patients with vasomotor rhinitis (VMR). Central nervous system stimulation
causes release of tachykinins, substance P (SP), calcitonin gene-related peptide (CGRP) and neurokinin A (NKA) that result in inhibition of the
sympathetic nervous system and shift the balance towards the parasympathetic response. Noradrenaline and neuropeptide tyrosine (NPY) cause
vasoconstriction and relief of nasal congestion. Vasodilators acetylcholine (Ach), vasoactive intestinal peptide (VIP) and nitric oxide (NO) cause
nasal congestion and glandular secretion [33].
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damage to the nasal mucosa. Histologically, severe
epithelial and sub epithelial damage can occur, such as
loss of ciliated cells as well as gaps and ruptures of
basal lamina. Furthermore, partial hyperplasia of goblet
cells and proliferated seromucous glands can be seen
[65].
Atrophic rhinitis is divided into primary (idiopathic)
or secondary rhinitis. Primary atrophic rhinitis is charac-
terized by nasal mucosal atrophy, dryness, crusting and
a foul smelling odor [66,67]. The cause is unknown, but
maybe associated directly or indirectly with Klebsiella
ozaenae, Staphlococcus aureus, Proteus mirabilis and
Escherichia coli from initial infection or secondary infec-
tion of already damaged nasal mucosa [68]. Secondary
atrophic rhinitis is more commonly due to chronic sinu-
sitis, granulomatous disease, excessive nasal turbinate
surgery, trauma or irridation [68]. A summary of the
proposed pathogeneses of non-allergic rhinitis is pro-
vided in Table 2.
Differential Diagnosis
As evidenced in the case presented and discussion
thereafter, thorough evaluation of rhinitis is critical for
proper care. There are many conditions that can mimic
both allergic and non-allergic rhinitis. These conditions
need to be considered in the differential diagnosis and
are listed in Table 3.
Concluding Remarks
Rhinitis is a prevalent condition, resulting in direct and
indirect costs in the billions of dollars. There are many
causes and often the treatments overlap. However, diag-
nosis can often be unclear and sometimes incorrect. A
thorough history and physical exam are vital, and inha-
lant allergy skin testing is essential to evaluate for aller-
gic etiology.
In the case we present here, the patient’s rhinorrhea
was twice misdiagnosed as due to allergic rhinitis or
VMR, before she sought allergy evaluation. Her CSF rhi-
norrhea, undiagnosed, could have resulted in serious
sequelae such as meningitis and possibly death. As well,
it could have been a sign of another underlying pathol-
ogy such as malignancy or tumor. In her case, we
believe the CSF leak was spontaneous, though it is diffi-
cult to prove whether prolonged moth ball exposure
and resultant toxicity may have played some role.
Non allergic rhinitis encompasses a vast and distinct
set of conditions. These conditions differ dramatically in
their pathogenesis and can differ in their treatments.
Evaluation of rhinitis by an allergy specialist is often
necessary to establish the correct diagnosis and treat-
ment regimen.
Table 2 Types of non-allergic rhinitis and proposed
mechanisms
RHINITIS PROPOSED MECHANISM
Non-Allergic Rhinitis:
Vasomotor Rhinitis CNS stimulation leading to
inhibition of the sympathetic
nervous system response and
enhancement of the
parasympathetic response[33].
Gustatory Rhinitis Muscarinc receptor stimulation
[45].
Infectious Rhinitis Typically viral or bacterial
induced inflammation[20].
Non-allergic rhinitis with
eosinophilia syndrome (NARES)
Eosinophilia leading to direct
nasal mucosal damage and
decreased mucocilliary
clearance[48-53].
Occupational Rhinitis: [54-58]
Annoyance Subjective without evidence of
inflammation.
Irritant Substance P induced
neutrophilic inflammation.
Corrosive Agent directly damages nasal
mucosa.
Allergic IgE mediated.
Other Rhinitis Syndromes: [60-63]
Hormonally induced Rhinitis Increased circulating blood
volume and possible hormonal
influences (e.g. estrogen,
progesterone) leading to
vascular pooling and smooth
muscle relaxation causing nasal
congestion.
Rhinitis Medicamentosa Direct mucosal damage by
alpha-adrenergic agent causing
loss of ciliated cells and
interstitial edema[64,65].
Atrophic Rhinitis: [66-68]
Primary Atrophic Rhinitis Infectious i.e. Klebsiella ozaenae
Secondary Atrophic Rhinitis Identifiable causes: Chronic
sinusitis, turbinate surgery and
irradiation
Listed above are some of the proposed mechanisms for the different types of
non-allergic rhinitis.
Table 3 Conditions that Mimic Rhinitis Symptoms
Nasal polyps
Anatomic abnormalities: E.g. Trauma or nasal tumors (Benign or
Malignant)
Autoimmune: e.g. Sjogren syndrome, SLE, Relapsing polychondritis,
Churg-Straus syndrome or Wegener granulomatosis
Metabolic: e.g. Hypothyroidism or acromegaly.
CSF Rhinorrhea
Primary Ciliary Dyskinesia
Cystic fibrosis
Immunodeficiency
Adapted from Wallace et al [21].
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